Prospective Randomized Study of Doxorubicin-Eluting-Bead Embolization in the Treatment of Hepatocellular Carcinoma: Results of the PRECISION V Study

Altekruse SF, McGlynn KA, Reichman ME (2009) Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 27:1485–1491

Höpfner M, Schuppan D, Scherübl H (2008) Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer. World J Gastroenterol 14:1–14

Llovet JM, Bru C, Bruix J (1999) Prognosis of hepatocellular carcinoma: The BCLC staging classification. Semin Liver Dis 19:329–338

Bruix J, Llovet JM (2002) Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 35:519–524

O’Neil BH, Venook AP (2007) Hepatocellular carcinoma: the role of the North American GI Steering Committee Hepatobiliary Task Force and the advent of effective drug therapy. Oncologist 12:1425–1432

Bruix J, Sherman M (2005) Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 42:1208–1236

Gish RG, Porta C, Lazar L et al (2007) Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. J Clin Oncol 25:3069–3075

Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390

Raoul JL, Heresbach D, Bretagne JF et al (1992) Chemoembolisation of hepatocellular carcinomas. A study of the biodistribution and pharmacokinetics of doxorubicin. Cancer 70:585–590

Lin DY, Liaw YF, Lee TY, Lai CM (1988) Hepatic arterial embolisation in patients with unresectable hepatocellular carcinoma—a randomised controlled trial. Gastroenterology 94:453–456

Group d’Etude et de Traitment du Carcinome Hépatocellulaire (1995) A comparison of lipiodol chemoembolisation and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 332:1256–1261

Raoul JL, Guyader D, Bretagne JF et al (1997) Prospective randomized trial of chemoembolisation versus intra-arterial injection of 131I-labeled-iodized oil in the treatment of hepatocellular carcinoma. Hepatology 26:1156–1161

Bruix J, Llovet JM, Castells A et al (1998) Transarterial embolisation versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomised, controlled trial in a single institution. Hepatology 27:1578–1583

Pelletier G, Ducreux M, Gay F et al (1998) Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolisation: a multicentre randomised trial. J Hepatol 29:129–134

Lo CM, Ngan H, Tso WK et al (2002) Randomised controlled trial of transarterial lipiodol chemoembolisation for unresectable hepatocellular carcinoma. Hepatology 35:1164–1171

Llovet JM, Real MI, Montana X et al (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359:1734–1739

Llovet JM, Bruix J, for the Barcelona-Clínic Liver Cancer Group (2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolisation improves survival. Hepatology 37:429–442

Marelli L, Stigliano R, Triantos C et al (2007) Transarterial therapy for hepatocellular carcinoma: Which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Interv Radiol 30:6–25

Lewis AL, Gonzales MV, Lloyd AW et al (2006) DC Bead: in vitro characterisation of a drug-delivery device for transarterial chemoembolisation. J Vasc Interv Radiol 17:335–342

Lewis AL, Gonzalez MV, Leppard SW et al (2007) Doxorubicin eluting beads. 1. Effects of drug loading on bead characteristics and drug distribution. J Mater Sci Mater Med 18:1691–1699

Lewis AL, Taylor RR, Hall B et al (2006) Pharmacokinetic and safety study of doxorubicin-eluting beads in a porcine model of hepatic arterial embolisation. J Vasc Interv Radiol 17:1335–1343

Hong K, Khwaja A, Liapi E et al (2006) New intra-arterial drug delivery system for the treatment of liver cancer: preclinical assessment in a rabbit model of liver cancer. Clin Cancer Res 12:2563–2567

Varela M, Real MI, Burrel M et al (2007) Chemoembolisation of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 46:474–481

Poon RT, Tso WK, Pang RW et al (2007) A phase I/II trial of chemoembolisation for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead. Clin Gastroenterol Hepatol 5:1100–1108

Kettenbach J, Stadler A, Katzler IV et al (2008) Drug-loaded microspheres for the treatment of liver cancer: review of current results. Cardiovasc Interv Radiol 31:468–476

Malagari K, Chatzimichael K, Alexopöulou E et al (2008) Transarterial chemoembolisation of unresectable hepatocellular carcinoma with drug eluting beads: results of an open-label study of 62 patients. Cardiovasc Interv Radiol 31:269–280

Llovet JM, Di Bisceglie AM, Bruix J, Panel of Experts in HCC-Design Clinical Trials et al (2008) Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100:698–711

Moher D, Schulz KF, Altman DG (2001) The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 357:1191–1194

Hopewell S, Clarke M, Moher D et al (2008) CONSORT Group. CONSORT for reporting randomised trials in journal and conference abstracts. Lancet 371:281–283

Bruix J, Sherman M, Llovet JM et al (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35:421–430

Wang SK, Tsiatis AA (1987) Approximately optional one-parameter boundaries for group sequential trials. Biometrics 43:193–199

Satake M, Uchida H, Arai Y et al (2008) Transcatheter arterial chemoembolization (TACE) with lipiodol to treat hepatocellular carcinoma: survey results from the TACE study group of Japan. Cardiovasc Interv Radiol 31:756–761

Grosso M, Vignali C, Quaretti P et al (2008) Transarterial chemoembolization of hepatocellular carcinoma with drug-eluting microspheres: preliminary results from an Italian multicenter study. Cardiovasc Interv Radiol 31:1141–1149